Any new treatment undergoes years, even decades, of study and clinical studies, which involve people, encompass the final phases of cancer treatment research. Participating in a clinical study may be an important treatment option for many patients, who may be among the first to benefit from a new drug or therapy. About 50 percent of Roswell Park patients are eligible for a clinical study.
Roswell Park recently launched a Phase I trial to test the efficacy and safety of a dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse. Dendritic cells are the gatekeepers of the human immune system, defending against invaders like bacteria, viruses and cancer. The vaccine is expected to show great promise in patients with bladder, brain, breast, esophageal, gastrointestinal, hepatocellular, kidney, lung, melanoma, ovarian, prostate, sarcoma and uterine tumors. Developed at Roswell Park, the NY-ESO-1 dendritic cell vaccine will be manufactured in the Institute’s new Therapeutic Cell Production Facility using a unique FDA-approved process.
Vitamin D Therapy
In a nationally funded program at Roswell Park, Candace Johnson, PhD, President & CEO of Roswell Park and Wallace Chair in Translational Research, leads a team that analyzes the potential of vitamin D for cancer prevention and treatment.
In patients with advanced transitional cell carcinoma of the urinary tract, a combination of drugs may be prescribed to kill cancer cells or stop them from dividing. Researchers at Roswell Park are currently evaluating the effectiveness of the drugs gemcitabine hydrochloride, cisplatin, and bevacizumab versus gemcitabine hydrochloride, cisplatin and a placebo.
Participate In a Clinical Trial
Clinical research studies are available to patients with all stages and all types of genitourinary cancer. Search available clinical research studies for urethral cancer patients at Roswell Park, or call 1-800-ROSWELL (1-800-767-9355).